| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D213-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-455 |
| filingDate |
2009-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2012-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2012500850-A |
| titleOfInvention |
Prolyl hydroxylase inhibitor |
| abstract |
The present invention relates to certain pyrimidinedione N-substituted glycine derivatives of formula (I) that are antagonists of HIF prolyl hydroxylase and that are useful for the treatment of diseases such as anemia that benefit from inhibition of this enzyme. . |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-WO2014021281-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20150036219-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I583670-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014021281-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020519697-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11021478-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11655249-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7142406-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015163603-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-5843182-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2015163602-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9422240-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102018409-B1 |
| priorityDate |
2008-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |